Filter by Year:
Press Releases
-
Mar 09, 2023
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
-
Mar 01, 2023
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
-
Jan 09, 2023
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
-
Dec 05, 2022
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
-
Nov 22, 2022
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
-
Nov 14, 2022
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
-
Nov 09, 2022
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
-
Nov 08, 2022
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
-
Oct 27, 2022
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
-
Oct 26, 2022
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
Displaying 1 - 10 of 53